Illumina, Inc.
Illumina, Inc. Annual Meeting Results
Summary
Illumina, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 21, 2025. Stockholders approved the election of eleven directors to the Board, ratified the appointment of Ernst & Young LLP as the independent public accounting firm, approved the compensation of named executive officers on an advisory basis, and approved the Second Amended and Restated 2015 Stock and Incentive Plan. The meeting saw high approval rates for all proposals, reflecting strong support from the shareholders.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement